Table 2.
Complications, treatment, and clinical outcome in patients with COVID-19 during hospitalization.
| Characteristic | All (n = 222) | No cardiac injury (n = 187) | Cardiac injury (n = 35) | P-value |
|---|---|---|---|---|
| Complication | ||||
| AKI, n (%) | 8 (3.6) | 2 (1.1) | 6 (17.1) | <0.001 |
| ALF, n (%) | 12 (5.4) | 8 (4.3) | 4 (11.4) | 0.086 |
| ARDS, n (%) | 25 (11.3) | 4 (2.1) | 21 (60.0) | <0.001 |
| Therapy | ||||
| Glucocorticoid, n (%) | 62 (27.9) | 44 (23.5) | 18 (51.4) | 0.001 |
| Inotropics, n (%) | 10 (4.5) | 1 (0.5) | 9 (25.7) | <0.001 |
| LMWH, n (%) | 15 (6.8) | 4 (2.1) | 11 (31.4) | <0.001 |
| IVGc, n (%) | 28 (12.6) | 13 (7.0) | 15 (42.9) | <0.001 |
| Antivirus, n (%) | 20 (9.0) | 13 (7.0) | 7 (20.0) | <0.001 |
| Non-invasive mechanical ventilation, n (%) | 13 (5.9) | 2 (1.1) | 11 (31.4) | <0.001 |
| Invasive mechanical ventilation, n (%) | 21 (9.5) | 3 (1.6) | 18 (51.4) | <0.001 |
| CRRT, n (%) | 10 (4.5) | 1 (0.5) | 9 (25.7) | <0.001 |
| ECMO, n (%) | 2 (0.9) | 0 (0.0) | 2 (5.7) | 0.001 |
| Clinical outcome | ||||
| Death, n (%) | 21 (9.5) | 2 (1.1) | 19 (54.3) | <0.001 |
AST, aspartate aminotransferase; AKI, acute kidney injury; ALF, acute liver failure; ARDS, acute respiratory distress syndrome; LMWH, low molecular weight heparin; IVGc, intravenous glucocorticoids; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.